Louisiana State Employees Retirement System Buys New Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Louisiana State Employees Retirement System bought a new stake in Dynavax Technologies Co. (NASDAQ:DVAX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 64,700 shares of the biopharmaceutical company’s stock, valued at approximately $905,000. Louisiana State Employees Retirement System owned approximately 0.05% of Dynavax Technologies as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Dynavax Technologies by 9.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,081,789 shares of the biopharmaceutical company’s stock valued at $15,978,000 after purchasing an additional 95,690 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Dynavax Technologies by 20.5% in the third quarter. Bank of New York Mellon Corp now owns 1,359,729 shares of the biopharmaceutical company’s stock valued at $20,083,000 after purchasing an additional 231,731 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Dynavax Technologies by 8.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 80,820 shares of the biopharmaceutical company’s stock valued at $1,194,000 after purchasing an additional 6,339 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Dynavax Technologies by 4.7% in the third quarter. Teacher Retirement System of Texas now owns 36,484 shares of the biopharmaceutical company’s stock valued at $539,000 after purchasing an additional 1,652 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Dynavax Technologies by 3.1% during the third quarter. Vanguard Group Inc. now owns 9,146,891 shares of the biopharmaceutical company’s stock worth $135,100,000 after buying an additional 270,730 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Dynavax Technologies

In related news, CAO Justin Burgess sold 20,526 shares of Dynavax Technologies stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $12.78, for a total value of $262,322.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.98% of the company’s stock.

Analysts Set New Price Targets

DVAX has been the subject of several recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 23rd. The Goldman Sachs Group initiated coverage on shares of Dynavax Technologies in a research note on Thursday, February 1st. They set a “neutral” rating and a $20.00 price objective for the company. Finally, StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Friday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, Dynavax Technologies currently has an average rating of “Moderate Buy” and an average target price of $25.00.

Dynavax Technologies Stock Down 2.2 %

NASDAQ:DVAX opened at $11.17 on Friday. Dynavax Technologies Co. has a twelve month low of $10.06 and a twelve month high of $15.15. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -186.14 and a beta of 1.26. The stock has a fifty day simple moving average of $12.25 and a 200-day simple moving average of $13.21. The company has a current ratio of 13.81, a quick ratio of 12.96 and a debt-to-equity ratio of 0.41.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.